Literature DB >> 2400647

Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin.

M G Bianchetti1, C Kanaka, A Ridolfi-Lüthy, H P Wagner, A Hirt, L Paunier, E Peheim, O H Oetliker.   

Abstract

Renotubular handling of sodium, potassium (K) calcium (Ca), phosphate, hydrogen ions and glucose, and urinary concentrating ability were studied in three children (aged 8, 8.5, 11 years) with renal magnesium (Mg) loss, persisting for more than 2 years after discontinuation of cisplatin treatment for neuroblastoma. A group of healthy children served as controls. Besides renal Mg wasting, a clear-cut tendency towards reduced calciuria associated with normal or slightly elevated plasma Ca was observed. Plasma K tended to be low (3.4-3.7 mmol/l), and plasma chloride was normal. Plasma bicarbonate (HCO3) ranged from 24.9 to 27.8 mmol/l, and urinary pH was always less than 6.0, indicating a renal HCO3 threshold exceeding 24 mmol/l. Plasma creatinine levels, glucosuria and phosphaturia, and urinary concentrating capacity were adequate. Comparable features were found in three children (aged 4.5, 9, 13 years) with primary renotubular hypomagnesaemia-hypokalaemia and hypocalciuria. This study complements the picture of chronic cisplatin tubulopathy in childhood demonstrating that, apart from Mg wasting, a reduced Ca excretion, and a tendency to hypokalaemia and metabolic alkalosis exist. Thus cisplatin may induce renal functional damage identical to that found in primary renotubular hypomagnesaemia--hypokalaemia with hypocalciuria.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400647     DOI: 10.1007/bf00857658

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

1.  Letter: Hypomagnessemia as a cause of persistent hypokalemia.

Authors:  S Webb; D S Schade
Journal:  JAMA       Date:  1975-07-07       Impact factor: 56.272

2.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome.

Authors:  F C BARTTER; P PRONOVE; J R GILL; R C MACCARDLE
Journal:  Am J Med       Date:  1962-12       Impact factor: 4.965

3.  Metabolic studies in primary tubular hypomagnesaemia-hypokalaemia.

Authors:  M G Bianchetti; E Girardin; N Benador-Milsztajn; P C Sizonenko; L Paunier
Journal:  Magnes Res       Date:  1988-07       Impact factor: 1.115

4.  Relation between serum and urinary calcium with particular reference to parathyroid activity.

Authors:  M Peacock; W G Robertson; B E Nordin
Journal:  Lancet       Date:  1969-02-22       Impact factor: 79.321

5.  The influence of extracellular fluid volume on the renal bicarbonate threshold. A study of two children with Lowe's syndrome.

Authors:  O Oetliker; E Rossi
Journal:  Pediatr Res       Date:  1969-03       Impact factor: 3.756

Review 6.  Renal handling of calcium.

Authors:  E Kelepouris
Journal:  Am J Nephrol       Date:  1988       Impact factor: 3.754

7.  The pathogenetic spectrum of Bartter's syndrome.

Authors:  J H Stein
Journal:  Kidney Int       Date:  1985-07       Impact factor: 10.612

Review 8.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

9.  Tubulopathy in nephrolithiasis: consequence rather than cause.

Authors:  P Jaeger; L Portmann; J M Ginalski; A F Jacquet; E Temler; P Burckhardt
Journal:  Kidney Int       Date:  1986-02       Impact factor: 10.612

10.  Low urinary calcium excretion in Bartter's syndrome.

Authors:  A Rudin; M Aurell; J Wilske
Journal:  Scand J Urol Nephrol       Date:  1988
View more
  10 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Hypomagnesaemia and pregnancy.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2018-03-07

3.  Urinary chloride excretion distinguishes between renal and extrarenal metabolic alkalosis.

Authors:  S S Mersin; G P Ramelli; R Laux-End; M G Bianchetti
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

4.  Cisplatin therapy in infants: short and long-term morbidity.

Authors:  P R Brock; E C Yeomans; S C Bellman; J Pritchard
Journal:  Br J Cancer Suppl       Date:  1992-08

5.  The influence of age on nephrotoxicity following chemotherapy in children.

Authors:  R Skinner; A D Pearson; L Price; M G Coulthard; A W Craft
Journal:  Br J Cancer Suppl       Date:  1992-08

Review 6.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

Review 7.  Gitelman-like syndrome after cisplatin therapy: a case report and literature review.

Authors:  Kessarin Panichpisal; Freddy Angulo-Pernett; Sharmila Selhi; Kenneth M Nugent
Journal:  BMC Nephrol       Date:  2006-05-24       Impact factor: 2.388

Review 8.  Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis.

Authors:  James J DiNicolantonio; James H O'Keefe; William Wilson
Journal:  Open Heart       Date:  2018-01-13

9.  Cisplatin dose rate as a risk factor for nephrotoxicity in children.

Authors:  R Skinner; A D Pearson; M W English; L Price; R A Wyllie; M G Coulthard; A W Craft
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

Review 10.  Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.

Authors:  Roderick Skinner
Journal:  Pediatr Nephrol       Date:  2017-04-22       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.